Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL31512211 | 0.98 | KDM4E (0.44) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| SCHEMBL2590649 | 0.95 | KDM4E (0.46) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| SCHEMBL31512217 | 0.95 | KDM4E (0.46) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| Lithium Ion SCHEMBL11350422 | 0.95 | KDM4E (0.46) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| Zinc Ion SCHEMBL927086 | 0.95 | KDM4E (0.46) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| SCHEMBL1804097 | 0.95 | KDM4E (0.46) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| Water SCHEMBL31512210 | 0.93 | KDM4E (0.44) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| Water SCHEMBL22263593 | 0.93 | KDM4E (0.44) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| Water SCHEMBL31512212 | 0.93 | KDM4E (0.44) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| Water SCHEMBL31512215 | 0.93 | KDM4E (0.44) | KDM4EMAPK1HIF1ABBOX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119751315-A | Method for preparing acetyltaurine calcium salt and other acetyltaurine salts | 苏州满元生物科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119431198-A | Preparation method of magnesium acetyltaurate | 苏州满元生物科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-112174960-B | Toll-like receptor modulating 4, 6-diamino-pyrido [3,2-D ] pyrimidine compounds | 吉利德科学公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-115942870-A | Composition with virucidal and/or antiviral activity | 西姆莱斯股份公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115305215-A | Novel bacterial starter of the genus lactobacillus | 西姆莱斯股份公司 | 2022-11-08 | — | — | CN | disclosed |
| US-20150352072-A1 | ZINC N-ACETYL TAURINATE FOR THE TREATMENT OF PROSTATE CANCER | TRI INOV (FR) | 2015-12-10 | — | — | US | disclosed |
| US-9029419-B2 | Use of zinc N-acetyltaurinate | TRI-INOV (FR) | 2015-05-12 | — | — | US | disclosed |
| US-8674135-B2 | Functionalized ionic liquids, and methods of use thereof | UNIVERSITY OF SOUTH ALABAMA (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140051754-A1 | ZINC N-ACETYL TAURINATE FOR THE TREATMENT OF PROSTATE CANCER | TRI-INOV (FR) | 2014-02-20 | — | — | US | disclosed |
| US-20110003891-A1 | NOVEL USE OF ZINC N-ACETYLTAURINATE | TRI-INOV (FR) | 2011-01-06 | — | — | US | disclosed |
| EP-2243539-A2 | Functionalized ionic liquids, and methods of use thereof | UNIVERSITY OF SOUTH ALABAMA (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20100228035-A1 | Functionalized Ionic Liquids, and Methods of Use Thereof | UNIVERSITY OF SOUTH ALABAMA (US) | 2010-09-09 | — | — | US | disclosed |
| US-7744838-B2 | Functionalized ionic liquids, and methods of use thereof | UNIVERSITY OF SOUTH ALABAMA (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100152465-A1 | Functionalized Ionic Liquids, and Methods of Use Thereof | UNIVERSITY OF SOUTH ALABAMA (US) | 2010-06-17 | — | — | US | disclosed |
| US-20080112866-A1 | Functionalized ionic liquids, and methods of use thereof | UNIVERSITY OF SOUTH ALABAMA (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1556390-A4 | FUNCTIONALIZED IONIC LIQUIDS, AND METHODS OF USE THEREOF | UNIV SOUTH ALABAMA (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7208605-B2 | Functionalized ionic liquids, and methods of use thereof | UNIVERSITY OF SOUTH ALABAMA (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1556390-A2 | FUNCTIONALIZED IONIC LIQUIDS, AND METHODS OF USE THEREOF | University Of South Alabama (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040035293-A1 | Functionalized ionic liquids, and methods of use thereof | UNIVERSITY OF SOUTH ALABAMA | 2004-02-26 | — | — | US | disclosed |
| WO-2003086605-A2 | FUNCTIONALIZED IONIC LIQUIDS, AND METHODS OF USE THEREOF | UNIVERSITY OF SOUTH ALABAMA (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228035-A1 | Functionalized Ionic Liquids, and Methods of Use Thereof | TST, SCLY, MPST | KDM4E 4543/4885MAPK1 3348/4885HIF1A 4658/4885 |
| US-20100152465-A1 | Functionalized Ionic Liquids, and Methods of Use Thereof | TST, SCLY, MPST | KDM4E 4543/4885MAPK1 3348/4885HIF1A 4658/4885 |
| US-20040035293-A1 | Functionalized ionic liquids, and methods of use thereof | TST, SCLY, MPST | KDM4E 4543/4885MAPK1 3348/4885HIF1A 4658/4885 |
| US-20080112866-A1 | Functionalized ionic liquids, and methods of use thereof | TST, SCLY, MPST | KDM4E 4543/4885MAPK1 3348/4885HIF1A 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.